Robert H.I. Andtbacka
HiFiBiO Therapeutics (United States) · 239 works · 12,929 citations · h-index 43
Top works
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
- Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib
- Microscopic Tumor Burden in Sentinel Lymph Nodes Predicts Synchronous Nonsentinel Lymph Node Involvement in Patients With Melanoma
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- Aggresome Disruption: A Novel Strategy to Enhance Bortezomib-Induced Apoptosis in Pancreatic Cancer Cells
- Melanoma
- NCCN Guidelines Insights: Melanoma, Version 3.2016
- Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma
- Melanoma, Version 2.2013
- Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
- Incidence and Prevention of Venous Thromboembolism in Patients Undergoing Breast Cancer Surgery and Treated According to Clinical Pathways
- A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US
- Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma
- Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells